Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox vs deferoxamine in sickle cell disease patients with transfusional iron overload
2016-002583-14Phase 2
- Sponsor
- Novartis
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of deferasirox in sickle cell disease (SCD) and Transfusional Siderosis (2 arms), sponsored by Novartis. Primary endpoint: Number of participants with adverse events in the first 24 weeks of treatment.
02
Drugs
deferasirox
03
Conditions
sickle cell disease (SCD)Transfusional Siderosis
Beyond the preview
Go deeper on 2016-002583-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002583-14.